BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome
- 1 May 2009
- journal article
- research article
- Published by Elsevier in Human Pathology
- Vol. 40 (5) , 645-652
- https://doi.org/10.1016/j.humpath.2008.06.032
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphomaThe Journal of Pathology, 2006
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarrayBlood, 2004
- Cancer Survival and Incidence from the Surveillance, Epidemiology, and End Results (SEER) ProgramThe Oncologist, 2003
- MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphomaBlood, 2003
- The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Involvement ofBCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphomaGenes, Chromosomes and Cancer, 1998
- Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell LymphomaBlood, 1998
- BCL6 Gene Rearrangement and Other Cytogenetic Abnormalities in Diffuse Large Cell LymphomaLeukemia & Lymphoma, 1995